Answers are grounded in this paper and cite their sources.
CMV is the most common viral infection after HCT. Due to hematologic and renal toxicities, current antivirals are used preemptively after evidence of CMV replication; no drug is approved for CMV prophylaxis post-HCT. Brincidofovir (BCV, CMX001) is an orally bioavailable lipid conjugate of cidofovir with in vitro activity against common transplant-related human dsDNA viruses. In a Phase 2 trial, BCV 100 mg twice weekly (BIW) prevented CMV reactivation and was generally well tolerated.
No takes yet. Share an insight, caveat, or question.
Marty et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: